Interpretation of Policy-Pharmaceutical Intellectual Property Policies and Regulations under the New Situation
-
Day one morning2019.11.14
-
Pharmaceutical R&D Innovation and IP Protection -- Global VisionDay one afternoon2019.11.14
-
Case Sharing of Invalidity, Infringement, LitigationDay two morning2019.11.15
-
Opportunities and challenges for generics companies under the new situationDay two afternoon2019.11.15
Interpretation of Policy-Pharmaceutical Intellectual Property Policies and Regulations under the New Situation
Opening and Chairman’s Welcome Address
Medical Policy Interpretation under the Background of Patent Law Amendment
------ In December 2018, The Executive Meeting of The State Council deliberated and adopted the draft amendment to the patent law, which has been reviewed for the first time by the NPC and is expected to be completed within this year. In particular for innovative drugs added invention patent protection extended the exceptional provisions.
The innovation of Judicial Mechanism Promotes the Development of Pharmaceutical Intellectual Property
Networking Coffee Break
WIPO’s Patent Cooperation Treaty applications: global gateway for Pharma and Biotech. (TBD)
Networking Luncheon
Pharmaceutical R&D Innovation and IP Protection -- Global Vision
Intellectual Property Management Experience in Multinational Pharmaceutical Companies, Patent Layout Strategy, Litigation Strategy
PATENT INNOVATION: PATIENT VALUE FIRST
Hotspot Issues about Medicine Patent Litigation in China
Networking Coffee Break
Establishing The Internal Intellectual Property System under The New Legislative Landscape
Panel Discussion: Opportunities and Challenges of Pharmaceutical Enterprises under Patent Term Compensation System--- Global Vision and Its Implications for China
------- On January 4, 2019, 《Amendment to the patent law of the People's Republic of China (Draft)》 was published, which mentioned that "The State Council can decide to extend the patent term for the invention patent of innovative drugs that are synchronously applied for listing in China and abroad". New opportunities are opening up for new drug development in China.
------- Comparison of patent term compensation system between China and foreign countries
------- Opportunity or challenge under the new rules
Cocktail &Networking（Sponsorship Opportunities）
The end of the first day
Case Sharing of Invalidity, Infringement, Litigation
Opening Address
Latest Changes in European Patent Application and Review Procedures
-------On March 12, 2019, the European Patent Office (EPO) released the 2018 annual report, which showed that the number of patent applications in China increased significantly, and the growth in life sciences was the fastest, and Chinese pharmaceutical companies reached a peak in the layout of Europe.The European Patent Office (EPO) has just published a new edition of Guidelines for Examination. The new guidelines will take effect from November 1, 2018.
Analysis of Hot Cases of Recent Patent invalidation
Europe and American Pharmaceutical Patent litigation and its Enlightenment to Chinese Pharmaceutical Enterprises (TBD)
------ Will Brexit change anything for litigation?
------ Planning a European/US strategy
Networking Coffee Break
Application techniques and protection strategies for European and American biomedical patents
------ Internal review procedures and application
------ Recent successful intellectual property strategies and possible problems
------ How can the intellectual property findings be effectively incorporated into the patent drafting process to ensure the legitimacy of U.S. courts?
------ American vision
Panel Discussion: European, American and Japanese Medical Patent Examination Cases and its implications for Domestic Pharmaceutical Companies ------- Various countries' review process and standards
------- Changes in standards for creative review of patents
------- Research on the standards of repeated authorization review
Opportunities and challenges for generics companies under the new situation
Challenge Strategy and commercial value of Generic Drug Patents
The Strategy of Indian Generic Drug Companies in R&D and Pre-PA
Networking Coffee Break
Patent game in drug development
Recent Hot Patent Infringement Cases Analysis
------ With the advent of the patent cliff, the disputes increase between the primary drug companies and generic drug companies
Panel Discussion:
The Strategy of Generic Drug Companies to Enter the European and American Markets
------- Various countries' review process and standards
------- Changes in standards for creative review of patents
------- Research on the standards of repeated authorization review
Key Lee
+86 15801952437
+86 21 65650305
key@zenseegroup.com
Frank Zhang
+86 15021074081
+86 21 65650305
frank.zhang@zenseegroup.com
Ann Yang
marketing@zenseegroup.com
+86 21 65651072
Register Now
Please call the conference committee at 86 21 65650305 or fill in the form. We will contact you as soon as possible